Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Katharine L. Lewis; Collin K. Chin; Kate Manos; John Casey; Nada Hamad; Julie Crawford; Shir Jing Ho; Samar Issa; Andrew Grigg; Peter Wood; Maher K. Gandhi; Bryan Do; Loretta Nastoupil; Eliza A. Hawkes; Chan Y. Cheah

doi:10.1111/bjh.16946

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Katharine L. Lewis, Collin K. Chin, Kate Manos, John Casey, Nada Hamad, Julie Crawford, Shir Jing Ho, Samar Issa, Andrew Grigg, Peter Wood, Maher K. Gandhi, Bryan Do, Loretta Nastoupil, Eliza A. Hawkes, Chan Y. Cheah

Lymphoma-Myeloma

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8–16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.

Original language	English (US)
Pages (from-to)	1049-1053
Number of pages	5
Journal	British Journal of Haematology
Volume	192
Issue number	6
DOIs	https://doi.org/10.1111/bjh.16946
State	Published - Mar 2021

Keywords

BTK inhibitor
central nervous system
ibrutinib
lymphoma
novel

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.16946

Cite this

Lewis, K. L., Chin, C. K., Manos, K., Casey, J., Hamad, N., Crawford, J., Ho, S. J., Issa, S., Grigg, A., Wood, P., Gandhi, M. K., Do, B., Nastoupil, L., Hawkes, E. A., & Cheah, C. Y. (2021). Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. British Journal of Haematology, 192(6), 1049-1053. https://doi.org/10.1111/bjh.16946

Lewis, KL, Chin, CK, Manos, K, Casey, J, Hamad, N, Crawford, J, Ho, SJ, Issa, S, Grigg, A, Wood, P, Gandhi, MK, Do, B, Nastoupil, L, Hawkes, EA & Cheah, CY 2021, 'Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience', British Journal of Haematology, vol. 192, no. 6, pp. 1049-1053. https://doi.org/10.1111/bjh.16946

@article{da1b7bb22fc3497085b2097231a57271,

title = "Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience",

abstract = "Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8–16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.",

keywords = "BTK inhibitor, central nervous system, ibrutinib, lymphoma, novel",

author = "Lewis, {Katharine L.} and Chin, {Collin K.} and Kate Manos and John Casey and Nada Hamad and Julie Crawford and Ho, {Shir Jing} and Samar Issa and Andrew Grigg and Peter Wood and Gandhi, {Maher K.} and Bryan Do and Loretta Nastoupil and Hawkes, {Eliza A.} and Cheah, {Chan Y.}",

note = "Publisher Copyright: {\textcopyright} 2020 British Society for Haematology and John Wiley & Sons Ltd",

year = "2021",

month = mar,

doi = "10.1111/bjh.16946",

language = "English (US)",

volume = "192",

pages = "1049--1053",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Ibrutinib for central nervous system lymphoma

T2 - the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

AU - Lewis, Katharine L.

AU - Chin, Collin K.

AU - Manos, Kate

AU - Casey, John

AU - Hamad, Nada

AU - Crawford, Julie

AU - Ho, Shir Jing

AU - Issa, Samar

AU - Grigg, Andrew

AU - Wood, Peter

AU - Gandhi, Maher K.

AU - Do, Bryan

AU - Nastoupil, Loretta

AU - Hawkes, Eliza A.

AU - Cheah, Chan Y.

PY - 2021/3

Y1 - 2021/3

N2 - Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8–16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.

AB - Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We analysed 33 patients who received ibrutinib, alone or with other therapies, for PCNSL (n = 9) or SCNSL (n = 24). The objective response rate was 58% (complete response 55%). The median progression-free survival and overall survival for patients with PCNSL were both 3·1 months; for SCNSL, 10·2 and 11·5 months respectively. Only one invasive fungal infection was observed, despite concurrent or recent use of dexamethasone 8–16 mg daily in 14 patients (42%). Ibrutinib has encouraging activity in these aggressive malignancies.

KW - BTK inhibitor

KW - central nervous system

KW - ibrutinib

KW - lymphoma

KW - novel

UR - http://www.scopus.com/inward/record.url?scp=85088103694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088103694&partnerID=8YFLogxK

U2 - 10.1111/bjh.16946

DO - 10.1111/bjh.16946

M3 - Article

C2 - 32677095

AN - SCOPUS:85088103694

SN - 0007-1048

VL - 192

SP - 1049

EP - 1053

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 6

ER -

Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this